Brainstorm Cell Therapeutics (BCLI) Tops Q4 EPS by 1c

Note: EPS may not be comparable

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q4 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• Getty Realty (GTY) Reiterated at Market Outperform by Citizens on Investment Volumes
• UBS Upgrades Bajaj Finance Ltd. (BAF:IN) to Neutral